Adding the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib to abiraterone acetate plus prednisone delayed disease progression and postponed the onset of symptoms in patients with metastatic ...

The castration-sensitive prostate cancer market presents opportunities driven by rising prostate cancer incidences, an aging population, growing awareness, and improved early diagnosis. Successive ...

A large analysis of two major clinical trials has found that the spread of prostate cancer can be detected on imaging scans ...

Add Yahoo as a preferred source to see more of our stories on Google. A major international trial finds that adding niraparib to standard prostate cancer therapy delays disease progression. (CREDIT: ...

Please provide your email address to receive an email when new articles are posted on . Many men with metastatic hormone-sensitive prostate cancer have not received recommended first-line treatment.

Please provide your email address to receive an email when new articles are posted on . FDA granted approval to darolutamide for metastatic hormone-sensitive prostate cancer. Randomized phase 3 trial ...

Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...

Patients with metastatic hormone-sensitive prostate cancer had similar overall survival no matter whether metformin was added to standard of care in a randomized trial. Metformin use was associated ...